Korczynski Sherry sold $46K of AQST

Korczynski Sherry (Chief Commercial Officer) sold 8,750 shares of Aquestive Therapeutics, Inc. (AQST) at $5.22 on 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Korczynski Sherry
Published Sep 11, 2026, 3:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 3:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AQST
Neutral
low confidence
Mentioned
$AQST
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

The disclosed sale is modest and pre-arranged, offering limited actionable insight.

02

Market read

Routine insider sell with low trading relevance.

03

What to watch

The 10b5-1 plan indicates pre-scheduled sale, reducing interpretive weight.

Relevance 2/10Novelty 4/10Timing: Filed Sep 9, 2026; reported Sep 11, 2026

Background

Form 4 filings disclose insider trades; investors monitor for material signals.

Company-level read

Ticker impact

$AQSTNeutralLow confidence
Context

Chief Commercial Officer sold 8,750 shares for $45,675 via a 10b5-1 plan, reducing holdings to 235,689 shares.

Expected impact

Potential short-term dip of <1% if market reacts to insider sell.

Evidence & confidence

Sale amount is small ($45k) and follows a pre-arranged plan, limiting informational value.

Market effects

No material impact on the biotech sector; typical insider transaction.

Limited to US-listed biotech investors.

Minimal global relevance.

Counterpoint

Insider sell could be a routine liquidity event, not a negative signal.

Key entities

  • Korczynski Sherry

    Chief Commercial Officer of Aquestive Therapeutics

  • Aquestive Therapeutics, Inc.

    Biopharmaceutical company developing treatments for rare diseases

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.